The FDA approved Icotyde (icotrokinra) on March 18, 2026, for moderate-to-severe plaque psoriasis in adults and adolescents aged 12 and older weighing at least 40 kg. It is the first oral peptide designed to selectively block the interleukin-23 (IL-23) receptor pathway.

That “first oral peptide” designation is worth parsing. IL-23 inhibitors already exist — injectable biologics like guselkumab and risankizumab have transformed psoriasis treatment. What Icotyde achieves is delivering that mechanism as an oral pill rather than an injection. For a disease that requires long-term management, the difference between a daily pill and periodic injections is not trivial.

The clinical data are strong. In the Phase 3 ICONIC program — which enrolled more than 2,500 patients across multiple trials — approximately 70% of patients achieved clear or almost clear skin (IGA 0/1) by week 16, and 55% achieved PASI 90 (90% improvement in psoriasis severity). In head-to-head trials (ICONIC-ADVANCE 1/2), icotrokinra demonstrated superiority to deucravacitinib for skin clearance at both 16 and 24 weeks.

The safety profile was notable for what it didn’t show: adverse reaction rates were within 1.1% of placebo through 16 weeks, and no new safety signals emerged through 52 weeks.

This approval matters beyond psoriasis. Icotrokinra demonstrates that targeted peptide therapeutics can work as oral drugs for autoimmune conditions — a drug class that has been dominated by injectable biologics. It is a proof of concept for oral peptide pharmacology in areas where patients and physicians have wanted alternatives to needles.